Showing results (691-700 of 828) with videos related to
Sort By:
Pageof 83
Archives of Pathology & Laboratory Medicine|July 11, 2000
Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999P L Fitzgibbons, D L Page, D Weaver, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 17, 2023
Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 TrialCorey W Speers, W Fraser Symmans, William E Barlow, et al.Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 13, 2022
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classificationD Trapani, M A Franzoi, H J Burstein, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 15, 2000
Phase II evaluation of thalidomide in patients with metastatic breast cancerS M Baidas, E P Winer, G F Fleming, et al.British Journal of Clinical Pharmacology|December 12, 2019
Genetic variation in EPHA contributes to sensitivity to paclitaxel-induced peripheral neuropathyLauren A Marcath, Kelley M Kidwell, Kiran Vangipuram, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 20, 2007
Neoadjuvant docetaxel and capecitabine and the use of thymidine phosphorylase as a predictive biomarker in breast cancerRachel M Layman, Dafydd G Thomas, Kent A Griffith, et al.Pediatric Obesity|January 22, 2019
Child and parent reports of children's depressive symptoms in relation to children's weight loss response in family-based obesity treatmentRachel P Kolko Conlon, Kelly T Hurst, Jacqueline F Hayes, et al.Breast Cancer Research and Treatment|July 10, 2016
SWOG S0800 (NCI CDR0000636131): addition of bevacizumab to neoadjuvant nab-paclitaxel with dose-dense doxorubicin and cyclophosphamide improves pathologic complete response (pCR) rates in inflammatory or locally advanced breast cancerZ A Nahleh, W E Barlow, D F Hayes, et al.Proceedings of the National Academy of Sciences of the United States of America|September 23, 2003
EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsCelina G Kleer, Qi Cao, Sooryanarayana Varambally, et al.NPJ Breast Cancer|August 26, 2017
Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancerCorey Speers, Shuang G Zhao, Ben Chandler, et al.Pageof 83